Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab deruxtecan + capecitabine + bevacizumab
- Development stage
- Phase 2
- Lead developer
- Gruppo Oncologico Nord Ovest
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Trastuzumab deruxtecan + capecitabine + bevacizumab is an investigational combination therapy regimen being evaluated for the treatment of HER2-positive metastatic or locally advanced unresectable colorectal cancer. This triplet therapy combines three distinct mechanisms: trastuzumab deruxtecan (T-DXd), a HER2-directed antibody-drug conjugate that delivers a cytotoxic topoisomerase I inhibitor payload directly to HER2-expressing cells; capecitabine, an oral fluoropyrimidine carbamate that is enzymatically converted to 5-fluorouracil to inhibit DNA synthesis; and bevacizumab, a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF) to suppress tumor angiogenesis. The regimen is the focus of the Phase II CHIMERA study, led by the Gruppo Oncologico del Nord-Ovest (GONO), aimed at improving outcomes in patients with HER2-amplified colorectal cancer who have limited first-line options.
- Other names
- T-DXd + capecitabine + bevacizumabCHIMERA regimen
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on trastuzumab deruxtecan + capecitabine + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab deruxtecan + capecitabine + bevacizumab.